最新消息分類研發臨床進展

漢康生技 HCB301 於台灣完成第一期臨床試驗首位患者給藥HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301

HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.

4 月 08, 2026

HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path隨著科學顧問委員會（SAB）就胃癌藥證註冊路徑達成共識，漢康生技釋出 HCB101 具備「治療骨幹療法」潛力的明確訊號

HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.

4 月 03, 2026

HanchorBio Reports Early Taiwan IIT Signal in 2L CRC With Sustained Disease Control Beyond 37 Weeks漢康生技公布台灣研究者發起的臨床研究於二線大腸直腸癌之早期訊號，疾病控制可持續超過 37 週

HanchorBio today announced early findings from an ongoing investigator-initiated trial (IIT) in Taiwan evaluating HCB101-based combination therapy in patients with second-line colorectal cancer (CRC).

4 月 03, 2026

HanchorBio Reports Preliminary First-Line HER2+ Gastric Cancer Data for HCB101, Demonstrating 83.3% ORR漢康生技公布HCB101 HER2陽性胃癌一線治療初步數據 ORR達 83.3%

Hanchorbio's preliminary clinical observations from its ongoing Phase 1b/2a study evaluating HCB101-based combination therapy in first-line HER2-positive gastric cancer.

4 月 01, 2026

HanchorBio Presents First Dedicated HCB101 Head and Neck Cancer Data in Oral Presentation at ICHNO 2026漢康生技於2026 ESMO頭頸癌年會首次以口頭發表 HCB101 頭頸癌臨床數據

HanchorBio announced the first dedicated presentation of HCB101 clinical data in head and neck squamous cell carcinoma (HNSCC) in an oral presentation at ICHNO 2026 (the 10th International Congress on Innovative Approaches in Head and Neck Oncology), a joint ESTRO, EHNS, and ESMO congress, in Seville, Spain.

3 月 20, 2026

HanchorBio-Expands-Global-Patent-Protection-For-HCB101-With-Taiwan-Patent-Grant

HanchorBio Expands Global Patent Protection for HCB101 with Taiwan Grant漢康生技融合蛋白創新藥HCB101獲台灣專利核准

Taiwan grant adds to issued patents in the United States and Japan, further strengthening HCB101’s cross-border IP estate and supporting long-term development and partnering strategy.

3 月 17, 2026

HanchorBio Presents First Public Clinical Data for HCB301, a Tri-Specific Innate Checkpoint Molecule, at ESMO-TAT 2026漢康生技於 ESMO標靶抗癌治療大會首次公開 HCB301 人體臨床數據，展現三功能先天免疫檢查點分子的臨床開發潛力

HanchorBio, Inc. announced the presentation of first-in-human clinical data for HCB301 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.

3 月 16, 2026

HanchorBio Highlights Advancing HCB101 Clinical Program Across Monotherapy and Combination Settings at ESMO-TAT 2026漢康生技於 ESMO標靶抗癌治療大會公布 HCB101 單藥與聯合治療臨床進展，展現作為先天免疫檢查點治療骨幹的潛力

HanchorBio announced the presentation of updated clinical data for HCB101 at the ESMO Targeted Anticancer Therapies (TAT) Congress 2026 in Paris, France.

3 月 16, 2026

HanchorBio Presents Dose-Dependent Tumor Responses and Deepening Tumor Shrinkage with HCB101 Triple Combination in Second-Line Gastric Cancer at the 11th Asia-Pacific Gastroesophageal Cancer Congress漢康生技於第11屆亞太胃食管癌大會發表 HCB101 三藥聯合療法於二線胃癌之具劑量依賴性的腫瘤反應與持續腫瘤縮小數據

HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company pioneering transformative immunotherapies, today presented new clinical data from its ongoing HCB101-201 Phase 1b/2a study at the 11th Asia-Pacific Gastroesophageal Cancer Congress (APGCC). The poster highlights early findings supporting dose-dependent antitumor activity of HCB101 in combination with ramucirumab and paclitaxel among patients with advanced gastric adenocarcinoma who progressed after first-line therapy.

3 月 05, 2026

HanchorBio Presents Monotherapy and Combination Clinical Data for HCB101 at AACR Immuno-Oncology 2026漢康生技於美國癌症研究協會 (AACR) 腫瘤免疫學年會發表 HCB101 單藥與聯合治療的臨床數據

HanchorBio Presents Monotherapy and Combination Clinica […]

2 月 19, 2026